Literature DB >> 3802110

Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.

P A Cassileth, C B Begg, R Silber, A Spiers, P T Burkart, W Scharfman, W H Knospe, J M Bennett, J J Mazza, M M Oken.   

Abstract

Thirty-five adults with acute nonlymphocytic leukemia who were in complete remission after initial induction therapy received a single course of high-dose cytarabine and amsacrine as consolidation therapy. No further therapy was administered. Despite substantial toxicity, the median duration of disease-free survival was 12 months, and 30% of patients are projected to be alive in continuous complete remission at 3 years. A single course of intensive postremission chemotherapy provides long-term disease-free survival in the absence of any further treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3802110

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

Review 1.  Acute myelogenous leukaemia in children.

Authors:  S O Lie
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

2.  A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.

Authors:  F Mandelli; M L Vegna; G Avvisati; S Amadori; A Spadea; E Cacciola; N Cantore; A De Laurenzi; C De Rosa; G Fioritoni
Journal:  Ann Hematol       Date:  1992-04       Impact factor: 3.673

Review 3.  High-dose cytosine arabinoside: pharmacological and clinical aspects.

Authors:  W G Peters; L P Colly; R Willemze
Journal:  Blut       Date:  1988-01

Review 4.  [Post-remission treatment of acute leukemia in adulthood: allogeneic bone marrow transplantation or chemotherapy?].

Authors:  U Jehn; R Grunewald
Journal:  Klin Wochenschr       Date:  1988-07-15

Review 5.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

6.  High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study.

Authors:  P Parikh; R Powles; J Treleaven; G Helenglass; M Gore; M Rose; D Talbot; S Milan; C Smith; R Pinkerton
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.